(DIR) Home
        
        
       Bill Hwang arrives in court for trial over collapse of his $36 billion
       Archegos fund
        
 (HTM) Source
        
       ----------------------------------------------------------------------
        
       Item 1 of 3 Sung Kook (Bill) Hwang, the founder and head of a private
       investment firm known as Archegos exits the Manhattan federal
       courthouse in New York City, U.S., April 27, 2022.
       REUTERS/Shannon/File Photo
        
        **[1/3]** Sung Kook (Bill) Hwang, the founder and head of a private
       investment firm known as Archegos exits the Manhattan federal
       courthouse in New York City, U.S., April 27, 2022.
       REUTERS/Shannon/File Photo Purchase Licensing
        
       NEW YORK, May 8 (Reuters) - Sung Kook "Bill" Hwang arrived in court
       Wednesday for the start of his criminal racketeering trial over the
       collapse of Archegos Capital Management, facing charges that he and a
       deputy broke the law in a massive stock scheme that unraveled in just
       days in 2021.
        
       Hwang appeared in a dark suit and purple tie in the Manhattan federal
       courtroom for the first day of screening potential jurors.
        
       The potential jurors were called into the judge's chambers one by one
       for an initial round of questioning, which will focus on whether they
       can sit for the expected eight weeks of trial.
        
       Those who pass that hurdle will face more detailed questioning
       regarding their suitability on Thursday before the final panel is
       chosen.
        
       The trial will delve into the implosion of Hwang's lightly regulated
       family investment office, which prosecutors allege caused more than
       $100 billion in shareholder losses at companies in its portfolio.
        
       Federal prosecutors accuse Hwang of using derivatives to secretly
       amass positions in multiple stocks that were so large they eclipsed
       that of the companies' largest investors, driving up stock prices.
        
       They also claim Hwang and former Archegos Chief Financial Officer
       Patrick Halligan then lied about their holdings to sustain their
       business relationship with global banks.
        
       Hwang and Halligan
        
       are charged with racketeering conspiracy
        
       . Hwang faces an additional 10 counts of fraud and market
       manipulation, and Halligan an additional two counts of fraud.
        
       The two men have pleaded not guilty and are expected to argue
       prosecutors are pushing a novel and nonsensical market manipulation
       theory. Several attorneys
        
       told Reuters
        
       it may be a tough case for prosecutors.
        
       Hwang's lawyers have described the case as the "most aggressive open
       market manipulation case ever" brought by prosecutors.
        
       Each count carries a maximum potential sentence of 20 years.
        
       Archegos head trader William Tomita and Chief Risk Officer Scott
       Becker have pleaded guilty to related charges and are expected to
       testify at the trial.
        
       Opening statements are expected on Monday before 12 jurors and four
       alternates. The judge has said there are unlikely to be proceedings on
       Fridays.
        
       Archegos' March 2021 collapse stemmed from Hwang's use of financial
       contracts known as total return swaps to take outsized stakes in his
       favorite holdings without actually owning the stock.
        
       Authorities have said Archegos borrowed aggressively to boost trading
       capacity and at its peak had $36 billion in assets and $160 billion of
       exposure to equities. Falling stock prices in March 2021 triggered
       margin calls that Archegos was unable to meet.
        
       That led some banks to dump stocks backing his swaps, causing big
       losses for Archegos and its lenders,
        
       such as Credit Suisse
        
       , now part of UBS
        
       (UBSG.S)
        
       ,
        
       and Nomura Holdings (8604.T)
        
       .
        
       U.S. District Judge Alvin Hellerstein, who is overseeing the trial,
       rejected Hwang and Halligan's motion to dismiss the case last year.
        
       Sign up here.
        
       Reporting by Jody Godoy; editing by Tom Hals and Michael Erman
        
       Our Standards: The Thomson Reuters Trust Principles.
        
       Brendan Pierson reports on product liability litigation and on all
       areas of health care law. He can be reached at
       brendan.pierson@thomsonreuters.com.
        
       Jody Godoy reports on banking and securities law. Reach her at
       jody.godoy@thomsonreuters.com
        
        
        
        
       ______________________________________________________________________
                                                 Served by Flask-Gopher/2.2.1